Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:44 PM
Ignite Modification Date:
2025-12-24 @ 7:44 PM
NCT ID:
NCT00030303
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Diagnosis of chronic phase chronic myelogenous leukemia
* Philadelphia chromosome positive
* Peripheral blast count no greater than 10%
* No molecular remission
* Less than 3 years since initial diagnosis
* No anticipation of requirement for bone marrow or stem cell transplantation for 6 months
PATIENT CHARACTERISTICS:
Age:
* 18 and over
Performance status:
* ECOG 0-1
Life expectancy:
* Not specified
Hematopoietic:
* Hemoglobin at least 10 g/dL
* Platelet count at least 20,000/mm\^3
Hepatic:
* Bilirubin less than 2.0 times upper limit of normal (ULN)
* Transaminase less than 2.0 times ULN
Renal:
* Creatinine less than 2.0 mg/dL
Other:
* Not pregnant
* Negative pregnancy test
* Fertile patients must use effective contraception
* No significant active infection requiring hospitalization
* No other serious illness or significant behavioral or psychological problem that would preclude study involvement
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* See Disease Characteristics
* Prior interferon alfa allowed
* No concurrent interferon alfa
Chemotherapy:
* Prior cytarabine or other cytotoxic agents allowed
* No concurrent cytarabine or other cytotoxic agents
* Concurrent hydroxyurea allowed
Endocrine therapy:
* No concurrent corticosteroid therapy
Radiotherapy:
* Not specified
Surgery:
* Not specified
Other:
* No concurrent immunosuppressive medications
* Concurrent imatinib mesylate allowed
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
120 Years
Study:
NCT00030303
Study Brief:
Protocol Section:
NCT00030303